Berlex’ Yaz User Fee Date Extended
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has extended the user fee date for Berlex' oral contraceptive Yaz by three months, parent company Schering AG said Dec. 9
You may also be interested in...
Berlex' Angeliq Approved, Will Launch In Mid-2006
The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.